Takeda Gmbh

Nycomed Gmbh

Astrazeneca Ab

Degenhard Marx

Armin Hatzelmann

Christof Zitt

Hans-Peter Kley

Beate Schmidt

Andrea Wohlsen

Geert Jan Sterk

Dieter Flockerzi

Anke Heuser

Hermann Tenor

Clemens Braun

Ulrich Kautz

Rolf-Peter Hummel

Christian Scheufler

Helgert Müller

Martin Feth

Wiro M P B Menge

Deborah Ockert

Johannes A M Christiaans

Torsten Dunkern

Raimund Külzer

Anna Rosiak

Klaus Dietzel

Jens Christoffers

Imre Schlemminger

Juergen Volz

Christian Weimar

Thomas Maier

Alexander Sudau

Christian Hesslinger

Stefan Fischer

Steffen Weinbrenner

Josef Stadlwieser

Christian Schudt

Heiko Bernsmann

Jürgen Volz

Rolf Beume

Thomas Stengel

Stefan-Lutz Wollin

Alexander Mann

Harald Ohmer

Saadia Eddahibi

Serge Adnot

Helgart Müller

Jörg Diefenbach

The invention relates to the combined use of a PDE4 inhibitor with a HMG-CoA reductase inhibitor for the prevention and curative treatment of an inflammatory pulmonary disease.

Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases

The compounds of Formula (I), are novel effective inhibitors of the type 4 phosphodiesterase.

Pyrazolone-derivatives and their use as PDE-4 inhibitors

The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase useful in the treatment of psoriasis or atopic dermatitis.

Pyrazolone derivatives as PDE4 inhibitors

The compounds of Formula (1), in which A, R1, R2, R3 and R5 have the meanings as given in the description, are novel effective inhibitors of type 4 and 5 phosphodiesterase.

3,4,4a,10b-Tetrahydro-1H-thiopyrano-[44,3-c] isoquinoline derivatives

The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase.

The invention relates to the use of Roflumilast, Roflumilast N-Oxide or a pharmaceutically acceptable salt of either for the treatment of pulmonary hypertension. The invention additionally relates to the use of Roflumilast, Roflumilast N-oxide or a pharmaceutically acceptable salt of either in combination with a PDE5 inhibitor or a pharmaceutically acceptable salt thereof for the treatment of pulmonary hypertension.

Roflumilast for the treatment of pulmonary hypertension

The subject matter of this application relates to the combination of ciclesonide with an antihistamine.

Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis

The compounds of Formula (I), in which R1, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the N-oxides of the compounds and the salts thereof and the stereoisomers of the compounds, the salts, the N-oxides of the compounds and the N-oxides of the salts thereof are effective inhibitors of the type 5 phosphodiesterase.

Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines

The compounds of a certain formula 1, in which R1, R7, R8, R9 and n have the meanings as given in the description, are novel effective inhibitors of the type 4 phosphodiesterase.

The subject matter of this application relates to the combination of ciclesonide or an epimer thereof with R,R-formoterol or a salt, or a hydrate of a salt thereof.

Combination medicament

The invention relates to the combination of ciclesonide with formoterol.

The present invention relates to a combination of ciclesonide with antihistamines.

The compounds of formula I in which R1, R2 and R3 have the meanings as given in the description, are novel effective PDE4 inhibitors.

3-oxa-10-aza-phenanthrenes

The compounds of formula I in which A, R1, R2 and R3 have the meanings as given in the description, are novel effective PDE4 inhibitors.

3-thia-10-aza-phenanthrene derivatives

Growing community of inventors

Moos, Germany

Degenhard Marx